-
Major pharmaceutical firms, including MSD and AstraZeneca, have announced significant cuts to UK investments, citing poor government support, undervaluation of medicines, and an uncompetitive environment. These decisions threaten the UK’s ambitions to be a global life sciences hub, with job losses and stalled projects. The government promises to act, but industry concerns persist.
-
On October 10, 2025, President Donald Trump announced a deal with AstraZeneca to lower drug prices for Medicaid patients by matching the lowest prices in developed countries. The agreement includes AstraZeneca's commitment to invest $50 billion in U.S. manufacturing by 2030 and participation in the upcoming TrumpRx website, which will sell discounted drugs directly to consumers starting in early 2026.
-
Major pharmaceutical firms, including AstraZeneca and Merck, are pausing or canceling planned investments in the UK due to a challenging business environment. This follows recent withdrawals and delays, with concerns over UK policy and economic conditions impacting future growth prospects.